{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:54:35Z","timestamp":1791161675500,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,5,13]],"date-time":"2009-05-13T00:00:00Z","timestamp":1242172800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cervical cancer is now considered the second leading cause of death among women worldwide, and its incidence has reached alarming levels, especially in developing countries. Similarly, high grade squamous intraepithelial lesion (HSIL), the precursor stage for cervical cancer, represents a growing health problem among younger women as the HSIL management regimes that have been developed are not fully effective. From the etiological point of view, the presence of Human Papillomavirus (HPV) has been demonstrated to play a crucial role for developing cervical malignancies, and viral DNA has been detected in 99.7% of cervical tumors at the later stages. CIGB-300 is a novel cyclic synthetic peptide that induces apoptosis in malignant cells and elicits antitumor activity in cancer animal models. CIGB-300 impairs the Casein Kinase (CK2) phosphorylation, by targeting the substrate's phosphoaceptor domain. Based on the perspectives of CIGB-300 to treat cancer, this \"first-in-human\" study investigated its safety and tolerability in patients with cervical malignancies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Thirty-one women with colposcopically and histologically diagnosed microinvasive or pre-invasive cervical cancer were enrolled in a dose escalating study. CIGB-300 was administered sequentially at 14, 70, 245 and 490 mg by intralesional injections during 5 consecutive days to groups of 7 \u2013 10 patients. Toxicity was monitored daily until fifteen days after the end of treatment, when patients underwent conization. Digital colposcopy, histology, and HPV status were also evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>No maximum-tolerated dose or dose-limiting toxicity was achieved. The most frequent local events were pain, bleeding, hematoma and erythema at the injection site. The systemic adverse events were rash, facial edema, itching, hot flashes, and localized cramps. 75% of the patients experienced a significant lesion reduction at colposcopy and 19% exhibited full histological regression. HPV DNA was negative in 48% of the previously positive patients. Long term follow-up did not reveal recurrences or adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>CIGB 300 was safe and well tolerated. This is the first clinical trial where a drug has been used to target the CK2 phosphoaceptor domain providing an early proof-of-principle of a possible clinical benefit.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-9-146","type":"journal-article","created":{"date-parts":[[2009,5,13]],"date-time":"2009-05-13T19:29:13Z","timestamp":1242242953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies"],"prefix":"10.1186","volume":"9","author":[{"given":"Ana M","family":"Solares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agueda","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idania","family":"Baladr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagnelia","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thelvia","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Sigman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E","family":"Perea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris E","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"L\u00f3pez-Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,5,13]]},"reference":[{"key":"1480_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nature03095","volume":"432","author":"C Sawyers","year":"2004","unstructured":"Sawyers C: Targeted cancer therapy. Nature. 2004, 432: 294-297. 10.1038\/nature03095.","journal-title":"Nature"},{"key":"1480_CR2","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1126\/science.1125951","volume":"312","author":"J Baselga","year":"2006","unstructured":"Baselga J: Targeting tyrosine kinases in cancer. Science. 2006, 312: 1175-1178. 10.1126\/science.1125951.","journal-title":"Science"},{"key":"1480_CR3","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature04874","volume":"441","author":"JS Sebolt-Leopold","year":"2006","unstructured":"Sebolt-Leopold JS, English JM: Mechanisms of drug inhibition of signaling molecules. Nature. 2006, 441: 457-462. 10.1038\/nature04874.","journal-title":"Nature"},{"key":"1480_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N","volume":"20","author":"B Guerra","year":"1999","unstructured":"Guerra B, Issinger O-G: Protein kinase CK2 and its role in cellular proliferation, development, and pathology. Electrophoresis. 1999, 20: 391-408. 10.1002\/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N.","journal-title":"Electrophoresis"},{"key":"1480_CR5","first-page":"573","volume":"16","author":"S Tawfic","year":"2001","unstructured":"Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K: Protein kinase CK2 signal in neoplasia. Histol Histopathol. 2001, 16: 573-582.","journal-title":"Histol Histopathol"},{"key":"1480_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0304-3835(96)04110-9","volume":"101","author":"RA Faust","year":"1996","unstructured":"Faust RA, Gapany M, Tristani P, Davis A, Adams GL, Ahmed K: Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation. Cancer Lett. 1996, 101: 31-35. 10.1016\/0304-3835(96)04110-9.","journal-title":"Cancer Lett"},{"key":"1480_CR7","first-page":"425","volume":"11","author":"W-M Chien","year":"2000","unstructured":"Chien W-M, Parker JN, Schmidt-Grimminger D-C, Broker TR, Chow LT: Casein kinase II phosphorylation of the human papillomavirus-18 E7 protein is critical for promoting s-phase entry. Cell Growth Differ. 2000, 11: 425-435.","journal-title":"Cell Growth Differ"},{"key":"1480_CR8","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1097\/00001813-200511000-00001","volume":"16","author":"KA Ahmed","year":"2005","unstructured":"Ahmed KA, Guixia W, Slaton J, Unger G, Ahmed K: TargetingCK2 for cancer therapy. Anti-Cancer Drugs. 2005, 16: 1037-43. 10.1097\/00001813-200511000-00001.","journal-title":"Anti-Cancer Drugs"},{"key":"1480_CR9","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/0008-5472.CAN-04-2086","volume":"64","author":"SE Perea","year":"2004","unstructured":"Perea SE, Reyes O, Puchades Y, Mendoza O, Vispo NS, Torrens I, Santos A, Silva R, Acevedo B, L\u00f3pez E, Falc\u00f3n V, Alonso DF: Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res. 2004, 64: 7127-29. 10.1158\/0008-5472.CAN-04-2086.","journal-title":"Cancer Res"},{"key":"1480_CR10","first-page":"36","volume-title":"Staging classification and clinical practice guidelines of gynecologic cancer","author":"JL Benedet","year":"2003","unstructured":"Benedet JL, Hacker NF, Ngan HY: FIGO Committee on Gynecologic Oncology, IGCS Guidelines Committee. Staging classification and clinical practice guidelines of gynecologic cancer. 2003, 36-40. [http:\/\/www.figo.org\/publications]2","edition":"2"},{"key":"1480_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00006250-199102000-00032","volume":"77","author":"A Stafl","year":"1991","unstructured":"Stafl A, Wilbanks GD: An international terminology of colposcopy: Report of the Nomenclature Committee of the International Federation of Cervical Pathology and Colposcopy. Obstet Gynecol. 1991, 77: 313-314.","journal-title":"Obstet Gynecol"},{"key":"1480_CR12","unstructured":"Cancer therapy Evaluation Program, CommonTerminology criteria for Adverse events, Version 3.0, DCTD, NCI, NIH, DHHS. 2003, [http:\/\/ctep.cancer.gov]"},{"key":"1480_CR13","first-page":"791","volume-title":"Principles of medical pharmacology","author":"CA Naranjo","year":"1998","unstructured":"Naranjo CA, Shear NH, Busto U: Adverse drug reactions. Principles of medical pharmacology. Edited by: Kalant H, Roschlau WHE. 1998, Oxford University Press: New York, 791-800. 6","edition":"6"},{"key":"1480_CR14","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/jcm.35.3.791-795.1997","volume":"35","author":"MV Jacobs","year":"1997","unstructured":"Jacobs MV, Snijders PJF, Brule van den AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM: A general primer GP5_\/GP6_-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997, 35: 791-795.","journal-title":"J Clin Microbiol"},{"key":"1480_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1386-6532(03)00167-7","volume":"29","author":"LW Huang","year":"2004","unstructured":"Huang LW, Chao SL, Chen PH, Chou HP: Multiple HPV genotypes in cervical carcinomas: improved DNA detection and typing in archival tissues. J Clin Virol. 2004, 29: 271-276. 10.1016\/S1386-6532(03)00167-7.","journal-title":"J Clin Virol"},{"key":"1480_CR16","doi-asserted-by":"crossref","unstructured":"Therase P: New Guidelines To Evaluate The Response To Treatment In Solid Tumors. Journal of the National Cancer Institute. 2000, 92 (3):","DOI":"10.1093\/jnci\/92.18.1534"},{"key":"1480_CR17","first-page":"161","volume":"9","author":"P Puligheddu","year":"1988","unstructured":"Puligheddu P, Marcello C, Medda F, Parodo G, Setzu A, Lecca U: Activity of interferon beta in condylomata with dysplastic lesion of the uterine cervix. Eur J Gynaecol Oncol. 1988, 9: 161-162.","journal-title":"Eur J Gynaecol Oncol"},{"key":"1480_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1089\/jir.1996.16.739","volume":"16","author":"R Garcia-Milian","year":"1996","unstructured":"Garcia-Milian R, Rios MA, Amigo M, D\u00edaz D, Silveira M, Guilar O, Amig\u00f3 M, Ara\u00f1a MJ, Perea SE: Modulation of human papillomavirus type 16 mRNA in cervical invasive carcinoma patients by interferon- \u03b1 therapy. J IFN Cyt Res. 1996, 16: 739-743. 10.1089\/jir.1996.16.739.","journal-title":"J IFN Cyt Res"},{"key":"1480_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/BF00410116","volume":"101","author":"J Krusic","year":"2004","unstructured":"Krusic J, Kirhmajer V, Knezevic M, Iki\u00e6 D, Marici\u00e6 Z, Rode B, Jusi\u00e6 D, Soos E: Influence of human leukocyte interferon on squamous cell carcinoma of uterine cervix: clinical, histological and histochemical observations. J Cancer Res and Clin Oncol. 2004, 101: 309-315. 10.1007\/BF00410116.","journal-title":"J Cancer Res and Clin Oncol"},{"key":"1480_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1163\/156856001320290679","volume":"9","author":"AP Watt","year":"2001","unstructured":"Watt AP: Mast cells and peptide induced histamine release. Inflammopharmacology. 2001, 9: 421-434. 10.1163\/156856001320290679.","journal-title":"Inflammopharmacology"},{"key":"1480_CR21","first-page":"48","volume-title":"Comprehensive Gynecology","author":"W Droegemuller","year":"1987","unstructured":"Droegemuller W, Herbst AL, Michell Dr: Comprehensive Gynecology. 1987, St Louis, MO, CV Mosby Co, 48-51."},{"key":"1480_CR22","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0002-9378(96)70016-9","volume":"175","author":"FJ Montz","year":"1996","unstructured":"Montz FJ: Impact of therapy for cervical intraepithelial neoplasia on fertility. Pathogenesis, detection, management of cervical neoplasia. Am J Obst Gynecol. 1996, 175: 1129-1136. 10.1016\/S0002-9378(96)70016-9.","journal-title":"Am J Obst Gynecol"},{"key":"1480_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archderm.134.1.25","volume":"134","author":"L Edwards","year":"1998","unstructured":"Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, Hougham AJ, Schmitt KA: Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human Papillomavirus. Arch Dermatol. 1998, 134: 25-30. 10.1001\/archderm.134.1.25.","journal-title":"Arch Dermatol"},{"key":"1480_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/sti.76.3.162","volume":"76","author":"GV von Krogh","year":"2000","unstructured":"von Krogh GV, Lacey CJM, Gross G, Barrasso R, Schneider A: European course on HPV associated pathology guidelines for primary care physicians of anogenital warts. Sex Transm Inf. 2000, 76: 162-168. 10.1136\/sti.76.3.162.","journal-title":"Sex Transm Inf"},{"key":"1480_CR25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/00004347-199304000-00018","volume":"12","author":"AG Ostor","year":"1993","unstructured":"Ostor AG: Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993, 12: 186-192. 10.1097\/00004347-199304000-00018.","journal-title":"Int J Gynecol Pathol"},{"key":"1480_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.virol.2004.09.045","volume":"331","author":"AD Santin","year":"2005","unstructured":"Santin AD, Zhan F, Bignotti E, Siegel ER, Can\u00e9 S, Bellone S, Palmieri M, Anfossi S, Thomas M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S: Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005, 331: 269-91. 10.1016\/j.virol.2004.09.045.","journal-title":"Virology"},{"key":"1480_CR27","first-page":"169","volume":"12","author":"M Graflund","year":"2004","unstructured":"Graflund M, Sorbe B, Sigurdardottir S, Karlsson MG: Relation between HPV-DNA and expression of p53, bcl-2, p21WAF-1, MIB-1, HER-2\/neu and DNA ploidy in early cervical carcinoma: correlation with clinical outcome. Oncol Rep. 2004, 12: 169-176.","journal-title":"Oncol Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-9-146\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:10:53Z","timestamp":1630462253000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-9-146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,13]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1480"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-9-146","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,13]]},"assertion":[{"value":"14 October 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"146"}}